Thomas Aller, OD, FBCLA, has launched to summarize the latest data on myopia for busy eyecare professionals. The new website features the latest data highlights from research and peer-reviewed journals on leading-edge therapies for myopia, with a focus on evidence-based clinical data, practical treatment options and hands-on management strategies.

Aller, who has been conducting myopia control research for more than 25 years and holds several patents in the field of myopia, is currently a visiting scholar at the University of California, Berkeley School of Optometry, as well as an adjunct professor at the University of Houston College of Optometry. He is also on the Clinical Guidelines Committee for the International Myopia Institute; a clinical advisor for TreeHouse Eyes, an organization dedicated to finding myopia treatments for children; and on the advisory board for Visioneering Technologies, Inc., makers of the NaturalVue (etafilcon A) Multifocal 1 Day Contact Lenses and provider of an unrestricted educational grant to make the website possible.

Advisory Board members include: Jeffrey Cooper, MS, OD, FAAO, professor emeritus at the State University of New York (SUNY) College of Optometry;  S. Barry Eiden, OD, FAAO, president and medical director of North Suburban Vision Consultants, Ltd. and an assistant clinical professor at the University of Illinois, Chicago’s Department of Ophthalmology; Alan N. Glazier, OD, FAAO, Dipl ABO, founder of Shady Grove Eye and Vision Care, ODs on Facebook, and; Somi Oh, OD, FIAO, orthokeratologist of Eye Boutique Optometry in Santa Clara, consultant for Advance Vision Center of Optometry in San Jose, CA, and of Dreamlens Research Co. in Seoul; Christine Wildsoet, DipAppSc(Optom) BSc (PharmHons) PhD, FAAO, professor at the School of Optometry/Vision Science Program, University of California, Berkeley, head of the Berkeley Myopia Research Group, committee chair  for the International Myopia Institute, and advisory board member of MyFun, a European-based myopia research consortium.

“Myopia is one of the principal causes of vision deterioration worldwide, and it is increasing here in the U.S. and globally,” Aller said. “The good news is that new research and promising modalities are being rapidly introduced. With, ECPs will have immediate access to a centralized source of carefully vetted data developed to help them provide better vision for their patients.”


Leave A Reply